This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2010 Jan 5:340:b5493.

doi: 10.1136/bmj.b5493.

NICE and new: appraising innovation

Robin E Ferner¹, Dyfrig A Hughes, Jeffrey K Aronson

Affiliations

PMID: 20051468
DOI: 10.1136/bmj.b5493

NICE and new: appraising innovation

Robin E Ferner et al. BMJ. 2010.

. 2010 Jan 5:340:b5493.

doi: 10.1136/bmj.b5493.

Authors

Robin E Ferner¹, Dyfrig A Hughes, Jeffrey K Aronson

Affiliation

¹ West Midlands Centre For Adverse Drug Reactions, City Hospital, Birmingham B18 7QH.

PMID: 20051468
DOI: 10.1136/bmj.b5493

No abstract available

PubMed Disclaimer

Similar articles

Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
Henry DA, Hill SR, Harris A. Henry DA, et al. JAMA. 2005 Nov 23;294(20):2630-2. doi: 10.1001/jama.294.20.2630. JAMA. 2005. PMID: 16304078 No abstract available.
Quality, innovation, and value for money: NICE and the British National Health Service.
Pearson SD, Rawlins MD. Pearson SD, et al. JAMA. 2005 Nov 23;294(20):2618-22. doi: 10.1001/jama.294.20.2618. JAMA. 2005. PMID: 16304076
Considering the value associated with innovation in health technology appraisal decisions (deliberations): a NICE thing to do?
Green C. Green C. Appl Health Econ Health Policy. 2010;8(1):1-5. doi: 10.1007/BF03256161. Appl Health Econ Health Policy. 2010. PMID: 20038189 No abstract available.
Economic evaluation: an introduction.
Raftery J. Raftery J. BMJ. 1998 Mar 28;316(7136):1013-4. doi: 10.1136/bmj.316.7136.1013. BMJ. 1998. PMID: 9550969 Free PMC article. Review. No abstract available.
Health Technology Assessment in the UK.
Raftery J, Powell J. Raftery J, et al. Lancet. 2013 Oct 12;382(9900):1278-85. doi: 10.1016/S0140-6736(13)61724-9. Lancet. 2013. PMID: 24120204 Review.

See all similar articles

Cited by

Innovation as a value in healthcare priority-setting: the UK experience.
Charlton V, Rid A. Charlton V, et al. Soc Justice Res. 2019;32(2):208-238. doi: 10.1007/s11211-019-00333-9. Epub 2019 Apr 15. Soc Justice Res. 2019. PMID: 31281204 Free PMC article.
Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.
Campbell RJ, Gill SS, Bronskill SE, Paterson JM, Whitehead M, Bell CM. Campbell RJ, et al. BMJ. 2012 Jul 4;345:e4203. doi: 10.1136/bmj.e4203. BMJ. 2012. PMID: 22763393 Free PMC article.
The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.
Messori A, Maratea D, Nozzoli C, Bosi A. Messori A, et al. Pharmacoeconomics. 2011 Apr;29(4):269-85. doi: 10.2165/11585930-000000000-00000. Pharmacoeconomics. 2011. PMID: 21395348 Review.
Defining rewardable innovation in drug therapy.
Aronson JK, Ferner RE, Hughes DA. Aronson JK, et al. Nat Rev Drug Discov. 2012 Mar 30;11(4):253-4. doi: 10.1038/nrd3715. Nat Rev Drug Discov. 2012. PMID: 22460109
Patterns and predictors of physician adoption of new cardiovascular drugs.
Anderson TS, Lo-Ciganic WH, Gellad WF, Zhang R, Huskamp HA, Choudhry NK, Chang CH, Richards-Shubik S, Guclu H, Jones B, Donohue JM. Anderson TS, et al. Healthc (Amst). 2018 Mar;6(1):33-40. doi: 10.1016/j.hjdsi.2017.09.004. Epub 2017 Oct 21. Healthc (Amst). 2018. PMID: 29066168 Free PMC article.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
- Ovid Technologies, Inc.